NCT06292923Phase 2Active not recruiting

A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients

Study sponsor: Tiziana Life Sciences LTD · TLSA

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2026-09Estimated

Enrollment · participants54Estimated

Source updated2026-07-02Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-07-02 · 2 fields changed

Primary completion date changed

− Before

~~Nov 2025~~

+ After

Sep 2026

Recruitment status changed

− Before

~~Recruiting~~

+ After

Active not recruiting

Check registry source

Study details

Conditions studied

Secondary Progressive Multiple Sclerosis

Treatments or interventions studied

ForalumabDrug

Primary outcomes · main study measures

Read the study measures

measure: The number of patients with adverse event (AE) reports.; timeFrame: Throughout the study, an average of 12 weeks (3 months).; measure: Changes in the Total Nasal Symptom Score (TNSS).; description: The TNSS is the sum of scores over 24 hours and 2 weeks for nasal congestion, runny nose, nasal itching, sneezing, and difficulty sleeping. The TNSS is quantified using the following scale: None 0, Mild 1 (symptom clearly present but easily tolerated), Moderate 2 (symptom bothersome but tolerable), Severe 3 (symptom difficult to tolerate - interferes with activities).; timeFrame: TNSS is performed during the Screening Visit and during the Treatment Period at the first visit of Cycle 1, Cycle 2, Cycle 3, and Cycle 4 (each Cycle is 3 weeks).; measure: Change from baseline for [18F]PBR06-positron emission tomography (PET) scans for microglial activation after 12 weeks (3 months) of study treatment.; description: Subjects at all sites will undergo PET imaging with the radiotracer \[18F\]PBR06.; timeFrame: Subjects will undergo PET imaging prior to Week 1 (i.e., prior to dosing) and after Week 12 (after Cycle 4 at the PET sub-study site).

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history